Reversible methane storage in porous hydrogel supported clathrates

Methane gas hydrates are a promising alternative for storage and transport of natural gas. In this paper, porous poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(2-hydroxyethyl methacrylate-co-methacrylic acid) (PHEMA-co-MAA) hydrogel microspheres were synthesised and examined for their application as a reusable scaffold for methane storage in their hydrated form. The hydration kinetics, methane storage capacity of the hydrogel microspheres, and a mixed colloidal system made of hydrogel particles and dry-water droplets were investigated in a 300cm3 steel vessel at 273.2K and varying pressures. Hydration of methane in the mixed colloidal system is high in capacity and exceedingly reversible. Higher pressure and smaller size of hydrogel microspheres result in improved capacity and kinetics, however reduce the recyclability of hydration. The porous hydrogel particles alone are too soft for reuse and need to be improved for practical application. Porous hydrogel microspheres were synthesised and mixed with dry-water, forming a colloidal system. Formation of methane gas hydrates in the colloidal system was fast, and high in hydration capacity. The system is reusable for methane storage

Analysis of Differentially Expressed Proteins in Self-Paired Sera of Advanced Non-small Cell Lung Cancer Patients Responsive to Gefin

Background and objective All the advanced NSCLC patients that received EGFR-TKI therapy will eventually relapse after a period of efficacy. The aim of this study is to investigate the serum biomarkers as potential predictive factors for the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in advanced non-small cell lung cancer. Methods Twenty self-paired serum samples were collected from 9 advanced NSCLC patients that evaluated as disease control (SD or PR) after gefinitib therapy, at the time points of before and after gefinitib treatment but 2 weeks before being evaluated as disease progress. All samples were pre-separated by WCX microbeads, and then detected on the MALDI-TOF-MS platform of Bruker AutoflexTM. ClinProTools (Version: 2.1) was used to analyze the differentially expressed proteins. Results There were 7 protein peaks (m/z), 3242.09, 8 690.36, 2 952.64, 3 224.04, 1 450.51, 1 887.8 and 3 935.73 found statistically differentially expressed between the self-paired samples. Three proteins (3 242.09, 2 952.64 and 3 224.04) were down-regulated and four proteins (8 690.36, 1 450.51, 1 887.8 and 3 935.73) up-regulated in gefinitib treated sera. Conclusion The data here suggest that several specific protein peaks might indicate gefinitib resistance, yet the identities of these proteins and the mechanisms underlying the responsiveness to gefinitib treatment need further investigation

Exploration of potential novel drug targets and biomarkers for small cell lung cancer by plasma proteome screening

Background: Small cell lung cancer (SCLC) is characterized by extreme invasiveness and lethality. There have been very few developments in its diagnosis and treatment over the past decades. It is urgently needed to explore potential novel biomarkers and drug targets for SCLC.Methods: Two-sample Mendelian Randomization (MR) was performed to investigate causal associations between SCLC and plasma proteins using genome-wide association studies (GWAS) summary statistics of SCLC from Transdisciplinary Research Into Cancer of the Lung Consortium (nCase = 2,791 vs. nControl = 20,580), and was validated in another cohort (nCase = 2,664 vs. nControl = 21,444). 734 plasma proteins and their genetic instruments of cis-acting protein quantitative trait loci (pQTL) were used, whereas external plasma proteome data was retrieved from deCODE database. Bidirectional MR, Steiger filtering and phenotype scanning were applied to further verify the associations.Results: Seven significant (p < 6.81 × 10−5) plasma protein-SCLC pairs were identified by MR analysis, including ACP5 (OR = 0.76, 95% CI: 0.67–0.86), CPB2 (OR = 0.90, 95% CI: 0.86–0.95), GSTM3 (OR = 0.45, 95% CI: 0.33–0.63), SHMT1 (OR = 0.74, 95% CI: 0.64–0.86), CTSB (OR = 0.79, 95% CI: 0.71–0.88), NTNG1 (OR = 0.81, 95% CI: 0.74–0.90) and FAM171B (OR = 1.40, 95% CI: 1.21–1.62). The external validation confirmed that CPB2, GSTM3 and NTNG1 had protective effects against SCLC, while FAM171B increased SCLC risk. However, the reverse causality analysis revealed that SCLC caused significant changes in plasma levels of most of these proteins, including decreases of ACP5, CPB2, GSTM3 and NTNG1, and the increase of FAM171B.Conclusion: This integrative analysis firstly suggested the causal associations between SCLC and plasma proteins, and the identified several proteins may be promising novel drug targets or biomarkers for SCLC

Valid olfactory impairment tests can help identify mild cognitive impairment: an updated meta-analysis

BackgroundOlfactory testing is emerging as a potentially effective screening method for identifying mild cognitive impairment in the elderly population.ObjectiveOlfactory impairment is comorbid with mild cognitive impairment (MCI) in older adults but is not well-documented in subdomains of either olfactory or subtypes of cognitive impairments in older adults. This meta-analysis was aimed at synthesizing the differentiated relationships with updated studies.MethodsA systematic search was conducted in seven databases from their availability to April 2023. A total of 38 publications were included, including 3,828 MCI patients and 8,160 healthy older adults. Two investigators independently performed the literature review, quality assessment, and data extraction. The meta-analyses were conducted with Stata to estimate the average effects and causes of the heterogeneity.ResultsCompared to normal adults, MCI patients had severe impairments in olfactory function and severe deficits in specific domains of odor identification and discrimination. Olfactory impairment was more severe in patients with amnestic mild cognitive impairment than in patients with non-amnestic MCI. Diverse test instruments of olfactory function caused large heterogeneity in effect sizes.ConclusionValid olfactory tests can be complementary tools for accurate screening of MCI in older adults